We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Baxter Promotional eMail Gets FDA Untitled Reply
Baxter Promotional eMail Gets FDA Untitled Reply
August 1, 2008
Baxter Healthcare’s Feiba VH, a hemophilia therapy, is misbranded because the company disseminated a “clinical thank you email” that made misleading safety and efficacy claims, according to an FDA untitled letter.